AR006999A1 - Una composición inmunogénica, terapéutica o profiláctica , que comprende un polipéptido omp106 aislado, un anticuerpo aislado que se liga a dicho polipéptido y una vacuna que lo comprende. - Google Patents

Una composición inmunogénica, terapéutica o profiláctica , que comprende un polipéptido omp106 aislado, un anticuerpo aislado que se liga a dicho polipéptido y una vacuna que lo comprende.

Info

Publication number
AR006999A1
AR006999A1 ARP970101850A ARP970101850A AR006999A1 AR 006999 A1 AR006999 A1 AR 006999A1 AR P970101850 A ARP970101850 A AR P970101850A AR P970101850 A ARP970101850 A AR P970101850A AR 006999 A1 AR006999 A1 AR 006999A1
Authority
AR
Argentina
Prior art keywords
polypeptide
omp106
isolated
therapeutic
polypeptides
Prior art date
Application number
ARP970101850A
Other languages
English (en)
Spanish (es)
Original Assignee
Antex Biolog Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antex Biolog Inc filed Critical Antex Biolog Inc
Publication of AR006999A1 publication Critical patent/AR006999A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ARP970101850A 1996-05-03 1997-05-05 Una composición inmunogénica, terapéutica o profiláctica , que comprende un polipéptido omp106 aislado, un anticuerpo aislado que se liga a dicho polipéptido y una vacuna que lo comprende. AR006999A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/642,712 US7341727B1 (en) 1996-05-03 1996-05-03 M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same

Publications (1)

Publication Number Publication Date
AR006999A1 true AR006999A1 (es) 1999-10-13

Family

ID=24577687

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970101850A AR006999A1 (es) 1996-05-03 1997-05-05 Una composición inmunogénica, terapéutica o profiláctica , que comprende un polipéptido omp106 aislado, un anticuerpo aislado que se liga a dicho polipéptido y una vacuna que lo comprende.

Country Status (25)

Country Link
US (6) US7341727B1 (cg-RX-API-DMAC10.html)
EP (1) EP0900025B1 (cg-RX-API-DMAC10.html)
JP (2) JP4401437B2 (cg-RX-API-DMAC10.html)
CN (2) CN1222618C (cg-RX-API-DMAC10.html)
AR (1) AR006999A1 (cg-RX-API-DMAC10.html)
AT (1) ATE244016T1 (cg-RX-API-DMAC10.html)
AU (1) AU723528B2 (cg-RX-API-DMAC10.html)
BG (1) BG64832B1 (cg-RX-API-DMAC10.html)
BR (1) BR9711090A (cg-RX-API-DMAC10.html)
CA (1) CA2253636C (cg-RX-API-DMAC10.html)
CZ (1) CZ298034B6 (cg-RX-API-DMAC10.html)
DE (1) DE69723254T2 (cg-RX-API-DMAC10.html)
EA (1) EA002743B1 (cg-RX-API-DMAC10.html)
EE (1) EE04684B1 (cg-RX-API-DMAC10.html)
ES (1) ES2202624T3 (cg-RX-API-DMAC10.html)
GE (1) GEP20022695B (cg-RX-API-DMAC10.html)
HU (1) HU223004B1 (cg-RX-API-DMAC10.html)
NO (2) NO324816B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ332896A (cg-RX-API-DMAC10.html)
PL (3) PL189374B1 (cg-RX-API-DMAC10.html)
SK (1) SK284812B6 (cg-RX-API-DMAC10.html)
TW (1) TW541314B (cg-RX-API-DMAC10.html)
UA (1) UA68332C2 (cg-RX-API-DMAC10.html)
WO (1) WO1997041731A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA973809B (cg-RX-API-DMAC10.html)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335018B1 (en) * 1995-05-01 2002-01-01 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US6440425B1 (en) * 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US7341727B1 (en) * 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
AUPO652897A0 (en) 1997-04-30 1997-05-29 University Of Melbourne, The Synthetic peptide constructs for the diagnosis and treatment of periodontitis
GB9714276D0 (en) * 1997-07-08 1997-09-10 Univ Dundee Peptides and related compounds
US8129500B2 (en) 1997-12-10 2012-03-06 Csl Limited Porphyromonas gingivalis polypeptides and nucleotides
GB9808720D0 (en) 1998-04-23 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9810084D0 (en) 1998-05-11 1998-07-08 Cortecs Uk Ltd Proteins
GB9810193D0 (en) * 1998-05-12 1998-07-08 Smithkline Beecham Biolog Novel compounds
US6627728B1 (en) 1998-05-12 2003-09-30 Smithkline Beecham Biologicals S.A. Compounds from moraxella catarrhalis
GB9810285D0 (en) 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
US6541616B1 (en) 1998-10-01 2003-04-01 Antex Biologics Inc. Moraxella catarrhalis protein, gene sequence and uses thereof
HU229968B1 (hu) 1999-03-19 2015-03-30 Smithkline Beecham Biologicals S.A Sztreptokokkusz oltóanyag
US6673910B1 (en) 1999-04-08 2004-01-06 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to M. catarrhalis for diagnostics and therapeutics
AU4567300A (en) * 1999-05-24 2000-12-12 Smithkline Beecham Biologicals (Sa) Novel compounds
GB9915031D0 (en) * 1999-06-25 1999-08-25 Smithkline Beecham Biolog Novel compounds
AU1383901A (en) * 1999-09-14 2001-04-17 Smithkline Beecham Biologicals (Sa) Novel compounds
GB9921691D0 (en) * 1999-09-14 1999-11-17 Smithkline Beecham Sa Novel compounds
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
SE0102410D0 (sv) * 2001-07-04 2001-07-04 Arne Forsgren Novel surface exposed immunoglobulin D-binding protein from moraxella catarrhalis
JP4740738B2 (ja) 2002-08-02 2011-08-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
EP2425853A1 (en) 2005-04-08 2012-03-07 Wyeth LLC Multivalent Pneumococcal Polysaccharide-Protein Conjugate Composition
CN100357318C (zh) * 2005-10-11 2007-12-26 中山大学 美人鱼发光杆菌外膜蛋白w和编码序列及其制备方法和应用
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
EA014107B1 (ru) 2005-12-22 2010-10-29 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
CN104436180B (zh) 2006-01-17 2021-08-31 阿恩·福斯格伦 新的表面外露流感嗜血菌蛋白质(蛋白质E；pE)
JP2009544279A (ja) * 2006-06-27 2009-12-17 オーラル ヘルス オーストラリア ピーティーワイ リミテッド 歯周病の予防に有用なポルフィロモナス・ジンジバリスポリペプチド
US20100183662A1 (en) 2007-06-26 2010-07-22 Ralph Leon Biemans Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
SG183016A1 (en) * 2007-07-12 2012-08-30 Oral Health Australia Pty Ltd Biofilm treatment
EP2604692A1 (en) * 2007-07-12 2013-06-19 Oral Health Australia Pty Ltd Immunology treatment for biofilms
WO2009049013A2 (en) * 2007-10-09 2009-04-16 Tufts University Cholera vaccines
CA2735171C (en) 2008-08-29 2023-10-03 Oral Health Australia Pty Ltd Prevention, treatment and diagnosis of p.gingivalis infection
US8140041B2 (en) * 2009-08-27 2012-03-20 Mediatek Inc. Tunable capacitive device with linearization technique employed therein
ES2366735B1 (es) * 2009-10-08 2012-09-13 Fundación Pública Andaluza Para La Gestión De La Investigación En Salud De Sevilla Vacuna frente a acinetobacter baumannii.
US9759718B2 (en) 2009-11-23 2017-09-12 Cyvek, Inc. PDMS membrane-confined nucleic acid and antibody/antigen-functionalized microlength tube capture elements, and systems employing them, and methods of their use
US9700889B2 (en) 2009-11-23 2017-07-11 Cyvek, Inc. Methods and systems for manufacture of microarray assay systems, conducting microfluidic assays, and monitoring and scanning to obtain microfluidic assay results
US10065403B2 (en) 2009-11-23 2018-09-04 Cyvek, Inc. Microfluidic assay assemblies and methods of manufacture
US9500645B2 (en) 2009-11-23 2016-11-22 Cyvek, Inc. Micro-tube particles for microfluidic assays and methods of manufacture
US9651568B2 (en) 2009-11-23 2017-05-16 Cyvek, Inc. Methods and systems for epi-fluorescent monitoring and scanning for microfluidic assays
US9855735B2 (en) 2009-11-23 2018-01-02 Cyvek, Inc. Portable microfluidic assay devices and methods of manufacture and use
CN102713621B (zh) 2009-11-23 2016-10-19 西维克公司 用于施行化验的方法和设备
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
CN102869377A (zh) 2010-03-10 2013-01-09 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
CN103154034B (zh) 2010-04-13 2016-06-08 塞尔德克斯医疗公司 结合人cd27的抗体及其用途
US8501197B2 (en) 2010-04-30 2013-08-06 The Research Foundation for The State of New York Compositions and methods for stimulating immune response against Moraxella catarrhalis
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
WO2012129455A2 (en) 2011-03-22 2012-09-27 Cyvek, Inc Microfluidic devices and methods of manufacture and use
RU2481401C2 (ru) * 2011-07-15 2013-05-10 Государственное образовательное учреждение высшего профессионального образования "Уральская государственная медицинская академия Министерства здравоохранения и социального развития Российской Федерации" (ГОУ ВПО УГМА Минздравсоцразвития России) СПОСОБ ВЫЯВЛЕНИЯ β-ЛАКТАМАЗОПРОДУЦИРУЮЩИХ ОКСИДАЗОПОЗИТИВНЫХ ГРАМОТРИЦАТЕЛЬНЫХ ДИПЛОКОККОВ, ПОДОЗРИТЕЛЬНЫХ НА ПРИНАДЛЕЖНОСТЬ К MORAХELLA (BRANCHAMELLA) CATARRHALIS
EP2822689B1 (en) 2012-03-08 2023-07-26 Cyvek, Inc. Micro-tube particles for microfluidic assays and methods of manufacture
US11210432B2 (en) * 2013-08-20 2021-12-28 Janus Technologies, Inc. Method and apparatus for selectively snooping and capturing data for secure computer interfaces
EP3268037B1 (en) 2015-03-09 2022-08-31 Celldex Therapeutics, Inc. Cd27 agonists
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
US10228367B2 (en) 2015-12-01 2019-03-12 ProteinSimple Segmented multi-use automated assay cartridge
WO2017184619A2 (en) 2016-04-18 2017-10-26 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
IE87414B1 (en) 2017-05-30 2023-07-19 Glaxosmithkline Biologicals Sa Novel methods for manufacturing an adjuvant
CN111670044A (zh) 2017-12-01 2020-09-15 葛兰素史密丝克莱恩生物有限公司 皂苷纯化
SG11202010011RA (en) 2018-04-17 2020-11-27 Celldex Therapeutics Inc Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
WO2020030572A1 (en) 2018-08-07 2020-02-13 Glaxosmithkline Biologicals Sa Processes and vaccines
CN111157735B (zh) * 2018-11-07 2023-02-07 广州万孚生物技术股份有限公司 凝集性卡他莫拉菌单克隆抗体及其制备方法和应用
WO2020109365A1 (en) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
WO2020123444A1 (en) 2018-12-11 2020-06-18 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
BR112021024363A2 (pt) 2019-06-05 2022-03-22 Glaxosmithkline Biologicals Sa Purificação de saponina
CN111778226B (zh) * 2020-07-21 2022-04-05 东北师范大学 一种水稻耐碱胁迫相关的质膜H+-ATPase蛋白及其应用
MX2023011788A (es) 2021-04-09 2023-10-11 Celldex Therapeutics Inc Anticuerpos contra ilt4, anticuerpo biespecifico anti-ilt4/pd-l1 y usos de los mismos.
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage
EP4558170A1 (en) 2022-07-19 2025-05-28 GlaxoSmithKline Biologicals S.A. Continuous process for vaccine production

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675176A (en) * 1983-12-12 1987-06-23 Norden Laboratories Moraxella bovis protease vaccine
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
US5552146A (en) * 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
US5607846A (en) 1994-05-17 1997-03-04 Research Foundation Of State University Of New York Vaccine for moraxella catarrhalis
US6335018B1 (en) 1995-05-01 2002-01-01 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US6440425B1 (en) * 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US7341727B1 (en) * 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
GB9809683D0 (en) 1998-05-06 1998-07-01 Smithkline Beecham Biolog Novel compounds
GB9812163D0 (en) 1998-06-05 1998-08-05 Smithkline Beecham Biolog Novel compounds

Also Published As

Publication number Publication date
EP0900025A1 (en) 1999-03-10
AU3118097A (en) 1997-11-26
JP2000510696A (ja) 2000-08-22
BG102983A (en) 2000-05-31
CA2253636C (en) 2003-04-22
WO1997041731A1 (en) 1997-11-13
ZA973809B (en) 1997-12-01
PL189995B1 (pl) 2005-10-31
HK1021299A1 (en) 2000-06-09
ES2202624T3 (es) 2004-04-01
SK150998A3 (en) 1999-05-07
PL330935A1 (en) 1999-06-07
HUP9902695A3 (en) 2001-02-28
CN1223549A (zh) 1999-07-21
JP2008161194A (ja) 2008-07-17
EP0900025B1 (en) 2003-07-02
CZ298034B6 (cs) 2007-05-30
EA199800973A1 (ru) 1999-06-24
BR9711090A (pt) 1999-08-17
NO985113L (no) 1998-12-28
TW541314B (en) 2003-07-11
HUP9902695A2 (hu) 1999-12-28
DE69723254T2 (de) 2004-04-22
AU723528B2 (en) 2000-08-31
SK284812B6 (sk) 2005-12-01
NO985113D0 (no) 1998-11-02
US20020177200A1 (en) 2002-11-28
CN1800359A (zh) 2006-07-12
US7576179B2 (en) 2009-08-18
HU223004B1 (hu) 2004-03-01
HK1095358A1 (zh) 2007-05-04
EP0900025A4 (en) 2000-01-05
NO324816B1 (no) 2007-12-10
EE9800373A (et) 1999-04-15
US6214981B1 (en) 2001-04-10
US7128910B2 (en) 2006-10-31
NO20063711L (no) 1998-12-28
ATE244016T1 (de) 2003-07-15
EE04684B1 (et) 2006-08-15
JP4401437B2 (ja) 2010-01-20
BG64832B1 (bg) 2006-06-30
PL189375B1 (pl) 2005-07-29
US20080145916A1 (en) 2008-06-19
CA2253636A1 (en) 1997-11-13
US7341727B1 (en) 2008-03-11
CZ352498A3 (cs) 1999-06-16
US7914795B2 (en) 2011-03-29
DE69723254D1 (de) 2003-08-07
US20100021492A1 (en) 2010-01-28
CN1222618C (zh) 2005-10-12
PL189374B1 (pl) 2005-07-29
US20070087019A1 (en) 2007-04-19
GEP20022695B (en) 2002-05-27
NZ332896A (en) 2000-05-26
UA68332C2 (en) 2004-08-16
CN100415871C (zh) 2008-09-03
EA002743B1 (ru) 2002-08-29

Similar Documents

Publication Publication Date Title
AR006999A1 (es) Una composición inmunogénica, terapéutica o profiláctica , que comprende un polipéptido omp106 aislado, un anticuerpo aislado que se liga a dicho polipéptido y una vacuna que lo comprende.
PT851927E (pt) Compostos para imunoterapia e diagnostico de tuberculose
BR9708401A (pt) Vetores de vìrus de para-varìola
DE69943359D1 (de) Tumorassoziierte Antigenderivate der Mage-Familie, zur Herstellung von Fusionsproteinen mit T-Helper Epitope und Zusammensetzungen zur Impfung
ATE127345T1 (de) Stressproteine und verwendungen dafür.
ES2127829T3 (es) Expresion de proteinas recombinantes fusionadas en bacterias atenuadas.
PT1090033E (pt) Particulas de proteinas de envelope do hcv: utilizacao para vacinacao
MX9101526A (es) Nuevo metodo para tratar la depresion
NO984244D0 (no) Vaksinesammensetninger og fremgangsmÕter som er nyttige i Õ indusere immunbeskyttelse mot artritogene peptider som er involvert i patogenese av reumatoid artritt
YU48525B (sh) Protein, dnk koji kodira protein, rekombinantni vektor koji obuhvata dnk i postupak za proizovodnju proteina
AR009600A1 (es) Secuencia de acido nucleico y aminoacidos relacionados con helicobacter pylori y composiciones de vacuna de la misma.
AU612683B2 (en) Synthetic peptides, antibodies directed against them, and the use thereof
ES2194012T3 (es) Epitopo p1a1 y p1a2 de la gpiii a de plaquetas, su preparacion y uso.
DK0463053T3 (da) Fremstilling og anvendelse af anthelmintiske midler og beskyttende immunogener
SE9604296D0 (sv) New pharmaceutical formulation of polypeptides
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
DE69928947D1 (de) Moraxella catarrhalis basb034 polypeptide und verwendungen davon
DK43991D0 (da) Allele varianter af plasmodium falciparum merozoitoverfladeantigen
EA199801032A1 (ru) Белки zona pellucida для контрацепции
BR0112141A (pt) Peptìdeos, polipeptìdeo, composição, uso de um peptìdeo ou um polipeptìdeo, e, anticorpo
BR0016740A (pt) Antìgenos de esporozoìto de cryptosporidium
GB2314560A (en) Synthetic peptides of m. gallisepticum, antibodies thereto, their preparations and use
AR010517A1 (es) Compuestos y metodos para la inmunoterapia y diagnostico de tuberculosis
GB2244273A (en) Allelic variants of plasmodium falciparum merozoite surface antigen.

Legal Events

Date Code Title Description
FG Grant, registration